Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of tocilizumab vs systemic corticosteroids in hospitalized COVID-19 pneumonia
2020-001707-16Phase 3Active
- Sponsor
- Biogipuzkoa Health Research Institute
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Biogipuzkoa Health Research Institute. Primary endpoint: Respiratory status over first 7 days. Started Jul 2020; status: active.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001707-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001707-16.